COMMUNIQUÉS West-GlobeNewswire
 
      -   
  RYBREVANT®▼ (amivantamab) en association avec LAZCLUZE®▼ (lazertinib) réduit la résistance acquise à l’osimertinib dans le traitement de première intention du cancer du poumon non à petites cellules avancé avec mutations de l’EGFR09/09/2025
-   
  Scenic Biotech Appoints Dr. Roland W. Bürli as CSO to Advance Pipeline of Modifier Therapies in Neuro- and Metabolic Diseases09/09/2025
-   
  Tourmaline Bio Enters into Agreement to be Acquired by Novartis AG09/09/2025
-   
  Novartis to acquire Tourmaline Bio, complementing cardiovascular pipeline with pacibekitug for the treatment of atherosclerotic cardiovascular disease (ASCVD)09/09/2025
-   
  Amgen and Kyowa Kirin Announce Top-Line Results From Rocatinlimab Phase 3 ASCEND Long-Term Extension Study in Adults With Moderate to Severe Atopic Dermatitis09/09/2025
-   
  Valley Wellness to open luxury behavioral health facility in Corona, CA09/09/2025
-   
  Harrow Announces Pricing of $250.0 Million Offering of Senior Unsecured Notes Due 203008/09/2025
-   
  NurExone Receives U.S. Patent Allowance for Exosome Manufacturing, Strengthening Supply Chain Readiness08/09/2025
-   
  Onco360® Has Been Selected as a National Specialty Pharmacy Partner for Wayrilz™ (rilzabrutinib)08/09/2025
-   
  Sienna Senior Living Announces the Opening of Its Long-Term Care Community in North Bay and Retirement Community in Brantford, Ontario08/09/2025
-   
  PharmAla Completes Import of LaNeo MDMA for US Distribution08/09/2025
-   
  Immix Biopharma Announces Strategic Investment by Houston based Goose Capital, led by founding member Dr. Nancy T. Chang08/09/2025
-   
  Enovis Corporation Announces Time Change for Presentation at Baird 2025 Global Healthcare Conference08/09/2025
-   
  Ultragenyx Announces Positive Longer-term Data from Phase 3 Study of DTX401 AAV Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia (GSDIa)08/09/2025
-   
  NeuroOne® to Participate in Sidoti Small-Cap Conference on September 17th and 18th, 202508/09/2025
-   
  Rapport Announces Proposed Public Offering of Common Stock08/09/2025
-   
  Dianthus Therapeutics, Inc. Announces Proposed $150 Million Underwritten Public Offering08/09/2025
-   
  Abivax Presents First Half 2025 Financial Results08/09/2025
-   
  Nora Mental Health Opens New Location in Dallas, TX, Bringing Compassionate, Accessible Mental Health Care to the Community08/09/2025
Pages